In addition, as revealed by the evaluation of AML samples from different cytogenetic backgrounds, AML samples with TP53 mutations, 11q23 rearrangements and complex karyotypes genetic backgrounds associated with poor prognosis presented increased expression of ALDH2 (Fig. 1E). This evidence concerns the gene TP53 and acute myeloid leukemia.